Gastric Cancer and Intestinal Metaplasia: Differential Metabolic Landscapes and New Pathways to Diagnosis
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25179509 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Seong Ji Choi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, Republic of Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms, Metaplasia, Biomarkers, Tumor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, the Korean government, the Ministry of Education of Korea.
Abstract (Originalsprache)
Gastric cancer (GC) is the fifth most common cause of cancer-related death worldwide. Early detection is crucial for improving survival rates and treatment outcomes. However, accurate GC-specific biomarkers remain unknown. This study aimed to identify the metabolic differences between intestinal metaplasia (IM) and GC to determine the pathways involved in GC. A metabolic analysis of IM and tissue samples from 37 patients with GC was conducted using ultra-performance liquid chromatography with tandem mass spectrometry. Overall, 665 and 278 significant features were identified in the aqueous and 278 organic phases, respectively, using false discovery rate analysis, which controls the expected proportion of false positives among the significant results. sPLS-DA revealed a clear separation between IM and GC samples. Steroid hormone biosynthesis, tryptophan metabolism, purine metabolism, and arginine and proline metabolism were the most significantly altered pathways. The intensity of 11 metabolites, including N1, N2-diacetylspermine, creatine riboside, and N-formylkynurenine, showed significant elevation in more advanced GC. Based on pathway enrichment analysis and cancer stage-specific alterations, we identified six potential candidates as diagnostic biomarkers: aldosterone, N-formylkynurenine, guanosine triphosphate, arginine, S-adenosylmethioninamine, and creatine riboside. These metabolic differences between IM and GC provide valuable insights into gastric carcinogenesis. Further validation is needed to develop noninvasive diagnostic tools and targeted therapies to improve the outcomes of patients with GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, Republic of Korea.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.
- EN BIO, Cheongju-si 28494, Republic of Korea.
ORCID-Profile: Seong Ji Choi, Hyuk Soon Choi, Jae Min Lee, Seung Han Kim
Förderung
- National Research Foundation of Korea
- the Korean government
- the Ministry of Education of Korea
- Hanyang University
- the Ministry of Education
Zitieren
APA
Choi, S. J., Choi, H. S., Kim, H., Lee, J. M., Kim, S. H., Yoon, J. H., Keum, B., Kim, H. J., Chun, H. J., & Park, Y. H. (2024). Gastric Cancer and Intestinal Metaplasia: Differential Metabolic Landscapes and New Pathways to Diagnosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179509
Vancouver
Choi SJ, Choi HS, Kim H, Lee JM, Kim SH, Yoon JH, et al. Gastric Cancer and Intestinal Metaplasia: Differential Metabolic Landscapes and New Pathways to Diagnosis. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179509
BibTeX
@article{Choi2024,
author = {Choi, Seong Ji and Choi, Hyuk Soon and Kim, Hyunil and Lee, Jae Min and Kim, Seung Han and Yoon, Jai Hoon and Keum, Bora and Kim, Hyo Jung and Chun, Hoon Jai and Park, Youngja H},
title = {Gastric Cancer and Intestinal Metaplasia: Differential Metabolic Landscapes and New Pathways to Diagnosis},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25179509}
}
EUVIMED